Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best mid cap stocks to buy with highest upside potential. On May 6, Vaxcyte achieved a significant milestone by completing enrollment for its three Phase 3 adult clinical trials (OPUS-1, OPUS-2, and OPUS-3) evaluating VAX-31 for the prevention of invasive pneumococcal disease. The OPUS-1 study serves as a pivotal head-to-head comparison against current standards of care, PCV20 and PCV21, with topline results expected in Q4 2026. Results for the remaining two studies are anticipated in H1 2027.

The company also reported progress in its broader vaccine pipeline and pediatric programs. Enrollment is finished for the VAX-31 infant Phase 2 dose-finding study, with data expected by the end of the first half of 2027. Additionally, Vaxcyte plans to initiate a Phase 1 adult clinical study for VAX-A1, its candidate for Group A Strep prevention, in mid-2026.

Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials

Photo by cdc on Unsplash

Financially, Vaxcyte Inc. (NASDAQ:PCVX) remains in a strong position, reporting approximately $2.7 billion in cash and investments as of March 31. This balance, bolstered by a February equity offering, provides the necessary capital to advance its clinical trials, manufacturing capabilities, and commercial readiness. Management emphasized that these resources support the company’s objective to establish VAX-31 as a best-in-class pneumococcal vaccine.

Vaxcyte Inc. (NASDAQ:PCVX) engages in the development of vaccines for infectious diseases, focusing on conjugate vaccines and protein-based vaccines developed through a platform for cell-free protein synthesis technology.

While we acknowledge the risk and potential of PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCVX and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1